The Dales Report – We Set The Narrative – We Set The Narrative
The TDR Three Takeaways for Psilocybin Clinical Trials
Recent findings from scientific reviews, including one release this week in JAMA Psychiatry, reveal that psilocybin, the active ingredient in psychedelic “magic mushrooms”, does not pose a significant risk of paranoia or transient thought disorder. This insight is crucial as the therapeutic potential of psychedelics, especially for mental health treatments, gains attention. These studies, spanning from 1966 to last year, included a meta-analysis of double-blind clinical trials where psilocybin was used to treat anxiety and depression. The results indicate that while the active magic mushroom ingredient may cause acute side effects like headache, nausea, and dizziness, these effects are typically mild and resolve within 48 hours.
Additionally, the safety profile of the psychedelic is reinforced by the infrequency of severe adverse effects such as paranoia and prolonged visual perceptual effects. These effects, when they occur, are manageable and transient, further confirming the controlled safety of psilocybin in therapeutic settings.
As research progresses, the role of licensed therapists in managing the psychedelics adverse effects and the overall effectiveness of various medications and alternative treatments in addressing these symptoms are critical areas for future studies. It is evident that the therapeutic use of this psychedelic has a safety profile that supports its continued investigation and potential application in mental health treatment strategies, potentially offering relief for millions suffering from anxiety, depression, and other mental health conditions. This ongoing research is essential in fostering broader acceptance and refined application of psilocybin in clinical settings. Want to keep up to date with all of TDR’s research and news, subscribe to our daily Baked In newsletter.
Read about other studies about Psilocybin on the TDR Website:
Bill (William McNarland, CFA) has over 25 years of experience in complementary areas of the capital markets, encompassing private equity and credit due diligence, economic and stock research and corporate finance. He has served on the boards of six different companies and has fulfilled roles as a Trustee and member of the Investment Review Committee for regulated investment funds. Having completed nine degrees and designations, with a notable distinction as a Chartered Financial Analyst, Bill is currently advancing his academic pursuits with a Master’s in Psychology. Furthermore, he is a published author of seven books, all of which are available on Amazon.
Psychedelic Assisted Therapy and Employee Benefits
Silo Pharma Advances Alzheimer’s Disease Treatment with SPC-14
Alaska’s Legislative Progress on Psychedelics for PTSD
‘Whiz’ Buckley Shares Perspective On Trading, Veteran Suicide
Latest Articles
Could Crypto Legislation help pass the SAFER Banking Act?
Bitcoin has Volatile Weekend Before Halving event
New Hampshire Legalization Efforts Advance Amid Legislative Hurdles
Exploring Psilocybin’s Safety in Clinical Trials
Popular Interviews
How STORZ & BICKEL Is Upping The Vaporizer Game
Cybin’s CYB003 BTD And Oversubscribed Private Placement
Trade To Black: SNDL Q4 Earnings, Janet Yellen On SAFE Banking
State Series: The Florida Cannabis Market
This website uses cookies to improve your experience. We’ll assume you’re ok with this, but you can opt-out if you wish. Accept Read More
Exploring Psilocybin's Safety in Clinical Trials – The Dales Report
